{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T17:44:05Z","timestamp":1783532645732,"version":"3.55.0"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,5,30]],"date-time":"2023-05-30T00:00:00Z","timestamp":1685404800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p>A number of vaccines have been developed and deployed globally to restrain the spreading of the coronavirus disease 2019 (COVID-19). The adverse effect following vaccination is an important consideration. Acute myocardial infarction (AMI) is a kind of rare adverse event after COVID-19 vaccination. Herein, we present a case of an 83-year-old male who suffered cold sweat ten minutes after the first inactivated COVID-19 vaccination and AMI one day later. The emergency coronary angiography showed coronary thrombosis and underlying stenosis in his coronary artery. Type II Kounis syndrome might be a potential mechanism, which is manifested as coronary thrombosis secondary to allergic reactions in patients with underlying asymptomatic coronary heart disease. We also summarize the reported AMI cases post COVID-19 vaccination, as well as overview and discuss the proposed mechanisms of AMI after COVID-19 vaccination, thus providing insights for clinicians to be aware of the possibility of AMI following COVID-19 vaccination and potential underlying mechanisms.<\/jats:p>","DOI":"10.3389\/fcvm.2023.1123385","type":"journal-article","created":{"date-parts":[[2023,5,30]],"date-time":"2023-05-30T09:42:47Z","timestamp":1685439767000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Acute myocardial infarction after inactivated COVID-19 vaccination: a case report and literature review"],"prefix":"10.3389","volume":"10","author":[{"given":"Weimei","family":"Ou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoming","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Licheng","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhixian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaimin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangfeng","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengmin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaokai","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuyuan","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,5,30]]},"reference":[{"key":"B1","year":""},{"key":"B2","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s40119-021-00248-0","article-title":"Cardiovascular complications of SARS-CoV-2 vaccines: an overview","volume":"11","author":"Shiravi","year":"2022","journal-title":"Cardiol Ther"},{"key":"B3","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1056\/NEJMoa2110475","article-title":"Safety of the BNT162b2 mRNA COVID-19 vaccine in a nationwide setting","volume":"385","author":"Barda","year":"2021","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1056\/NEJMoa2101544","article-title":"Safety and efficacy of single-dose Ad26.COV2.S vaccine against COVID-19","volume":"384","author":"Sadoff","year":"2021","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1093\/ageing\/afaa274","article-title":"Efficacy and safety of COVID-19 vaccines in older people","volume":"50","author":"Soiza","year":"2021","journal-title":"Age Ageing"},{"key":"B8","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"key":"B9","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/S1473-3099(20)30843-4","article-title":"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18\u201359 years: a randomised, double-blind, placebo-controlled, phase 1\/2 clinical trial","volume":"21","author":"Zhang","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1056\/NEJMoa2200674","article-title":"Safety and efficacy of a third dose of BNT162b2 COVID-19 vaccine","volume":"386","author":"Moreira","year":"2022","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines10050700","article-title":"Cardiac adverse events after vaccination-A systematic review","volume":"10","author":"Parmar","year":"2022","journal-title":"Vaccines"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/qjmed\/hcab252","article-title":"Acute myocardial infarction and myocarditis following COVID-19 vaccination","author":"Aye","year":"2021","journal-title":"QJM"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1001\/jama.2021.13443","article-title":"Myocarditis and pericarditis after vaccination for COVID-19","volume":"326","author":"Diaz","year":"2021","journal-title":"JAMA"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1080\/03007995.2022.2078081","article-title":"COVID-19 and cardiovascular disease: manifestations, pathophysiology, vaccination, and long-term implication","volume":"38","author":"Abdel Moneim","year":"2022","journal-title":"Curr Med Res Opin"},{"key":"B15","doi-asserted-by":"publisher","first-page":"2939","DOI":"10.1002\/jmv.27688","article-title":"Characterization of the significant decline in humoral immune response six months post-SARS-CoV-2 mRNA vaccination: a systematic review","volume":"94","author":"Notarte","year":"","journal-title":"J Med Virol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1080\/10408363.2022.2038539","article-title":"Effects of age, sex, serostatus, and underlying comorbidities on humoral response post-SARS-CoV-2 pfizer-BioNTech mRNA vaccination: a systematic review","volume":"59","author":"Notarte","year":"","journal-title":"Crit Rev Clin Lab Sci"},{"key":"B17","doi-asserted-by":"publisher","first-page":"6588","DOI":"10.1002\/jmv.27214","article-title":"Safety of COVID-19 vaccines","volume":"93","author":"Al Khames Aga","year":"2021","journal-title":"J Med Virol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/S0140-6736(21)01429-X","article-title":"Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey","volume":"398","author":"Tanriover","year":"2021","journal-title":"Lancet"},{"key":"B19","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s11684-021-0893-y","article-title":"A review of the safety and efficacy of current COVID-19 vaccines","volume":"16","author":"Huang","year":"2022","journal-title":"Front Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"e2140364","DOI":"10.1001\/jamanetworkopen.2021.40364","article-title":"Analysis of COVID-19 vaccine type and adverse effects following vaccination","volume":"4","author":"Beatty","year":"2021","journal-title":"JAMA Netw Open"},{"key":"B21","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1186\/s12916-021-02059-5","article-title":"Evaluation of the safety profile of COVID-19 vaccines: a rapid review","volume":"19","author":"Wu","year":"2021","journal-title":"BMC Med"},{"key":"B22","doi-asserted-by":"publisher","first-page":"101077","DOI":"10.1016\/j.cpcardiol.2021.101077","article-title":"Clinical cardiovascular adverse events reported post-COVID-19 vaccination: are they a real risk?","volume":"47","author":"Hana","year":"2022","journal-title":"Curr Probl Cardiol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"10109","DOI":"10.12998\/wjcc.v10.i28.10109","article-title":"Link between COVID-19 vaccines and myocardial infarction","volume":"10","author":"Zafar","year":"2022","journal-title":"World J Clin Cases"},{"key":"B24","doi-asserted-by":"publisher","first-page":"e11385","DOI":"10.1016\/j.heliyon.2022.e11385","article-title":"Myocardial infarction following COVID-19 vaccine administration; a systematic review","volume":"8","author":"Baqi","year":"2022","journal-title":"Heliyon"},{"key":"B25","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.ijcard.2005.08.007","article-title":"Kounis syndrome (allergic angina and allergic myocardial infarction): a natural paradigm?","volume":"110","author":"Kounis","year":"2006","journal-title":"Int J Cardiol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"e84","DOI":"10.1016\/j.ijcard.2013.07.044","article-title":"Anaphylaxis mediated myocardial infarction in a coronary graft: a new variant of Kounis syndrome (a case report)","volume":"168","author":"Dazy","year":"2013","journal-title":"Int J Cardiol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1515\/cclm-2016-0010","article-title":"Kounis syndrome: an update on epidemiology, pathogenesis, diagnosis and therapeutic management","volume":"54","author":"Kounis","year":"2016","journal-title":"Clin Chem Lab Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hcac001","article-title":"Kounis syndrome must be considered in the differential diagnosis of myocardial infarction following COVID-19 vaccination","author":"Allam","year":"2022","journal-title":"QJM"},{"key":"B29","doi-asserted-by":"publisher","first-page":"e71","DOI":"10.1016\/j.jemermed.2021.04.018","article-title":"Type 1 Kounis syndrome induced by inactivated SARS-COV-2 vaccine","volume":"61","author":"Ozdemir","year":"2021","journal-title":"J Emerg Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hcac001","article-title":"Allergic reactions to current available COVID-19 vaccinations: pathophysiology, causality, and therapeutic considerations","volume":"9","author":"Kounis","year":"2021","journal-title":"Vaccines"},{"key":"B31","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.jaci.2018.01.034","article-title":"Mast cells signal their importance in health and disease","volume":"142","author":"Olivera","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"50","DOI":"10.7774\/cevr.2014.3.1.50","article-title":"Vaccine allergies","volume":"3","author":"Chung","year":"2014","journal-title":"Clin Exp Vaccine Res"},{"key":"B33","doi-asserted-by":"publisher","first-page":"3018","DOI":"10.1093\/eurheartj\/ehaa548","article-title":"Mast cell tryptase level should be checked in all patients with suspected Kounis syndrome","volume":"41","author":"Khan","year":"2020","journal-title":"Eur Heart J"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3390\/v14081644","article-title":"Myocardial infarction following COVID-19 vaccine administration: post hoc, ergo propter hoc?","volume":"14","author":"Baronti","year":"2022","journal-title":"Viruses"},{"key":"B35","doi-asserted-by":"publisher","first-page":"S46","DOI":"10.1016\/j.jcpa.2007.04.012","article-title":"Mechanisms underlying adverse reactions to vaccines","volume":"137","author":"Siegrist","year":"2007","journal-title":"J Comp Pathol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.amjcard.2021.09.032","article-title":"Acute myocardial infarction within 24 hours after COVID-19 vaccination: is Kounis syndrome the culprit?","volume":"1","author":"Kounis","year":"","journal-title":"Am J Cardiol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.jccase.2022.01.014","article-title":"Recurrent Kounis syndrome\u2014a life-threatening event after COVID-19 vaccine administration","volume":"25","author":"Fialho","year":"2022","journal-title":"J Cardiol Cases"},{"key":"B38","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.jccase.2022.05.001","article-title":"Hypersensitivity coronary myocardial infarction (Kounis syndrome) and COVID-19 vaccines","volume":"26","author":"Kounis","year":"","journal-title":"J Cardiol Cases"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijid.2022.08.026","article-title":"Clinical cardiovascular emergencies and the cellular basis of COVID-19 vaccination: from dream to reality?","volume":"124","author":"Li","year":"2022","journal-title":"Int J Infect Dis"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2023.1123385\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,30]],"date-time":"2023-05-30T09:42:50Z","timestamp":1685439770000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2023.1123385\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,30]]},"references-count":39,"alternative-id":["10.3389\/fcvm.2023.1123385"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2023.1123385","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,30]]},"article-number":"1123385"}}